{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:36:36Z","timestamp":1793424996927,"version":"4.5.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH R01 HL119718"],"award-info":[{"award-number":["NIH R01 HL119718"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 HL101422"],"award-info":[{"award-number":["U01 HL101422"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01 HL101389"],"award-info":[{"award-number":["U01 HL101389"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 AR070253"],"award-info":[{"award-number":["P30 AR070253"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Low-dose MTX (LD-MTX) has been associated with a reduced risk of cardiovascular disease (CVD) among patients with systemic rheumatic diseases but not among the general population. Prior reports suggest that LD-MTX may reduce blood pressure (BP). We studied the effect of LD-MTX on BP.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Method<\/jats:title>\n                  <jats:p>We examined data that compared LD-MTX to placebo in a randomized double-blind controlled clinical trial conducted among patients who had known CVD but without rheumatic disease. Systolic and diastolic BP (SBP, DBP) were collected as vital sign measurements at each scheduled study visit during 5 years of follow-up. Longitudinal SBP and DBP were compared between patients of LD-MTX and placebo arms using a linear mixed model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Result<\/jats:title>\n                  <jats:p>Data were used from 2391 patients randomized to LD-MTX and 2395 to placebo, with a mean follow-up of 26\u2009months. At baseline, SBP and DBP were normally distributed with similar medians [SBP: 128\u2009mmHg (IQR 118\u2013139), DBP: 74\u2009mmHg (IQR 67\u201380)] between patients from both treatment groups; 93% patients reported at baseline using at least one type of medication for hypertension. After treatment, compared with placebo, the estimated differences in changes of SBP and DBP in the LD-MTX group were &amp;lt;1\u2009mm (SBP: \u03b2 = \u20130.75\u2009mmHg, 95% CI \u20130.02 to \u20131.49; DBP: \u03b2 = \u20130.56\u2009mmHg, 95% CI \u20130.12 to \u20131.01).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Patients randomized to LD-MTX without systemic rheumatic disease had no clinically meaningful difference in BP compared with placebo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>ClinicalTrials.gov, http:\/\/clinicaltrials.gov, NCT 01594333.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae604","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T22:33:12Z","timestamp":1733869992000},"page":"3917-3920","source":"Crossref","is-referenced-by-count":3,"title":["Blood pressure changes during methotrexate treatment: results from a randomized placebo-controlled trial among patients with cardiovascular risk"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8657-1741","authenticated-orcid":false,"given":"Jing","family":"Cui","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M","family":"Ridker","sequence":"additional","affiliation":[{"name":"Division of Preventive Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H","family":"Solomon","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"key":"2025052703531157000_keae604-B1","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/CIRCRESAHA.121.318082","article-title":"Pathophysiology of hypertension: the mosaic theory and beyond","volume":"128","author":"Harrison","year":"2021","journal-title":"Circ Res"},{"key":"2025052703531157000_keae604-B2","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1001\/jama.290.22.2945","article-title":"C-reactive protein and the risk of developing hypertension","volume":"290","author":"Sesso","year":"2003","journal-title":"JAMA"},{"key":"2025052703531157000_keae604-B3","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.atherosclerosis.2012.05.013","article-title":"Endothelial dysfunction in rheumatic autoimmune diseases","volume":"224","author":"Murdaca","year":"2012","journal-title":"Atherosclerosis"},{"key":"2025052703531157000_keae604-B4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jbspin.2012.02.005","article-title":"Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis","volume":"80","author":"Dadoun","year":"2013","journal-title":"Joint Bone Spine Rev Rhum"},{"key":"2025052703531157000_keae604-B5","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1161\/01.CIR.0000054612.26458.B2","article-title":"Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis","volume":"107","author":"Solomon","year":"2003","journal-title":"Circulation"},{"key":"2025052703531157000_keae604-B6","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJM198503283121303","article-title":"Efficacy of low-dose methotrexate in rheumatoid arthritis","volume":"312","author":"Weinblatt","year":"1985","journal-title":"N Engl J Med"},{"key":"2025052703531157000_keae604-B7","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","article-title":"Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease","volume":"108","author":"Micha","year":"2011","journal-title":"Am J Cardiol"},{"key":"2025052703531157000_keae604-B8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1759720X17719850","article-title":"Methotrexate, blood pressure and markers of arterial function in patients with rheumatoid arthritis: a repeated cross-sectional study","volume":"9","author":"Mangoni","year":"2017","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025052703531157000_keae604-B9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/RHU.0000000000000736","article-title":"Initiation of disease-modifying therapies in rheumatoid arthritis is associated with changes in blood pressure","volume":"24","author":"Baker","year":"2018","journal-title":"J Clin Rheumatol"},{"key":"2025052703531157000_keae604-B10","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N Engl J Med"},{"key":"2025052703531157000_keae604-B11","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","article-title":"The changing landscape of atherosclerosis","volume":"592","author":"Libby","year":"2021","journal-title":"Nature"},{"key":"2025052703531157000_keae604-B12","first-page":"2589","article-title":"Therapeutic targeting of inflammation in hypertension: from novel mechanisms to translational perspective","volume":"117","author":"Murray","year":"2021","journal-title":"Cardiovasc Res"},{"key":"2025052703531157000_keae604-B13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1161\/HYPERTENSIONAHA.119.13642","article-title":"Effects of interleukin-1beta inhibition on blood pressure, incident hypertension, and residual inflammatory risk: a secondary analysis of CANTOS","volume":"75","author":"Rothman","year":"2020","journal-title":"Hypertension"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae604\/60972167\/keae604.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/6\/3917\/60972167\/keae604.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/6\/3917\/60972167\/keae604.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T07:53:27Z","timestamp":1748332407000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/6\/3917\/7918345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":13,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,12,6]]},"published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae604","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2024,12,6]]}}}